Mesoblast Limited
ASX: MSB
Mesoblast widens losses with falling revenue and high launch risks despite $161M raise.
(Source: TradingView) 3-Month Performance Profile of MSB on a DTF compared to S&P/ASX 200 (XJO).
Mesoblast’s H1 FY2025 results highlight mounting financial pressures, with net loss widening 45.41% YoY to $72.52 million despite a one-off inventory boost from FDA approval. Reve
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
